
    
      Study will evaluate long-term safety and tolerability of a new compound in the treatment of
      patients with schizophrenia as assessed by adverse events (AEs), measures of extra pyramidal
      symptoms (EPS; Abnormal Involuntary Movement Scale [AIMS], Barnes Akathisia Scale [BAS], and
      Simpson-Angus Rating Scale [SAS]), vital sign measurements, electrocardiograms (ECGs),
      clinical laboratory evaluations.
    
  